Uterine Cancer - Pipeline Review, H1 2014
Uterine Cancer - Pipeline Review, H1 2014
Summary
Global Markets Directs, Uterin...
early Stage Products 14
uterine Cancer - Products Under Development By Companies 15
uterine Cancer - Products Under Invest...
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Uterine Cancer - Pipel...
Upcoming SlideShare
Loading in...5
×

Uterine Cancer - Pipeline Review, H1 2014: Market Trends and Analysis Report

236

Published on

Uterine Cancer - Pipeline Review, H1 2014 @ http://www.researchmoz.us/uterine-cancer-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
236
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Uterine Cancer - Pipeline Review, H1 2014: Market Trends and Analysis Report"

  1. 1. Uterine Cancer - Pipeline Review, H1 2014 Uterine Cancer - Pipeline Review, H1 2014 Summary Global Markets Directs, Uterine Cancer - Pipeline Review, H1 2014, provides an overview of the Uterine Cancers therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Uterine Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Uterine Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 4 introduction 5 global Markets Direct Report Coverage 5 uterine Cancer Overview 6 therapeutics Development 7 pipeline Products For Uterine Cancer - Overview 7 pipeline Products For Uterine Cancer - Comparative Analysis 8 uterine Cancer - Therapeutics Under Development By Companies 9 uterine Cancer - Therapeutics Under Investigation By Universities/institutes 11 uterine Cancer - Pipeline Products Glance 12 late Stage Products 12 clinical Stage Products 13 Uterine Cancer - Pipeline Review, H1 2014
  2. 2. early Stage Products 14 uterine Cancer - Products Under Development By Companies 15 uterine Cancer - Products Under Investigation By Universities/institutes 16 uterine Cancer - Companies Involved In Therapeutics Development 17 azaya Therapeutics Incorporated 17 endoceutics, Inc. 18 sunshine Biopharma, Inc. 19 uterine Cancer - Therapeutics Assessment 20 assessment By Monotherapy Products 20 assessment By Target 21 assessment By Mechanism Of Action 24 assessment By Route Of Administration 27 assessment By Molecule Type 29 drug Profiles 31 acolbifene Hydrochloride - Drug Profile 31 product Description 31 mechanism Of Action 31 r&d Progress 31 angiotensin 1-7 - Drug Profile 32 product Description 32 mechanism Of Action 32 r&d Progress 32 docetaxel Liposomal - Drug Profile 34 product Description 34 mechanism Of Action 34 r&d Progress 34 adva-27a - Drug Profile 36 product Description 36 mechanism Of Action 36 r&d Progress 36 adva-32a - Drug Profile 38 product Description 38 mechanism Of Action 38 r&d Progress 38 compound-2 - Drug Profile 39 product Description 39 mechanism Of Action 39 r&d Progress 39 uterine Cancer - Recent Pipeline Updates 40 uterine Cancer - Dormant Projects 45 uterine Cancer - Product Development Milestones 46 featured News & Press Releases 46 aug 12, 2013: Advanomics Wins Research Grant For Cancer Drug Candidate 46 jun 19, 2013: Sunshine Biopharma's Anticancer Drug Candidate Adva-27a Is Unaffected By Recent Supreme Court Ruling On Patentability Of Human Genes 46 jan 15, 2013: Advanomics Files New Patent Application For Multidrug Resistance Adva-27a Anticancer Compound 46 dec 10, 2012: Sunshine Biopharma Completes Another Ind-enabling Study Of Adva-27a 47 jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of Ati-1123 47 appendix 49 methodology 49 coverage 49 secondary Research 49 primary Research 49 expert Panel Validation 49 contact Us 50 disclaimer 50 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 Uterine Cancer - Pipeline Review, H1 2014
  3. 3. USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Uterine Cancer - Pipeline Review, H1 2014

×